Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inebilizumab in Anti-NMDA Receptor Encephalitis
NCT04372615Phase 2Recruiting
- Sponsor
- University of Utah
- Start
- Mar 2022
- Primary completion
- Sep 2028
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in anti-NMDA receptor encephalitis comparing Inebilizumab Arm with Placebo Arm (2 arms). Primary endpoints: Modified Rankin Score at 16 weeks and Treatment-Emergent Adverse Events and Serious Adverse Events at 96 weeks. Started Mar 2022; status: recruiting.
02
Drugs
inebilizumab
03
Conditions
anti-NMDA receptor encephalitis
Beyond the preview
Go deeper on NCT04372615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04372615.